The Perth biotech startup you need to know about this month: how Meridian Therapeutics is reshaping rare disease treatment

Nestled in a converted heritage warehouse on Rokeby Road in Subiaco, Meridian Therapeutics is quietly building something that could reshape how Australia tackles rare genetic diseases. This month, the four-year-old biotech company announced a $24 million Series B funding round—a significant milestone for the local innovation ecosystem and a clear signal that Perth's tech sector is moving beyond software into deeper, more capital-intensive ventures.

The company's focus is deceptively simple: they're developing rapid genetic screening tools that can identify rare inherited disorders in newborns within days rather than weeks or months. For parents in remote Western Australian regions—where specialist diagnostic services remain scarce—this represents a genuine breakthrough. The technology has already been trialled at three major Perth hospitals, including a partnership with Fiona Stanley Hospital in Murdoch that began in early 2025.

What makes Meridian particularly interesting isn't just the science. It's the business model. Rather than pursuing the traditional pharma route of developing expensive drugs for small patient populations, they're creating a diagnostic platform designed to be accessible across regional and rural hospitals. Their test costs $890—roughly 40 per cent less than comparable international services—and integrates with existing pathology networks across Australia.

The funding round, led by Melbourne-based venture capital firm Blackbird Capital alongside existing backers, reflects growing confidence in Perth's ability to produce world-class life sciences innovation. It's a departure from the city's historical strength in resources and engineering sectors, yet it builds on existing infrastructure: proximity to Curtin University's genomics research groups, the growing bioscience precinct in the Perth CBD, and a relatively untapped pool of local scientific talent.

The company plans to use the capital for three priorities: expanding their laboratory capacity at their Subiaco facility, hiring 15 new genetic counsellors and bioinformaticians, and launching pilot programmes in Queensland and South Australia by early 2027. They're also investing in training programmes for rural healthcare workers—a move that underscores their commitment to accessibility over pure profit.

For Perth's broader tech narrative, Meridian represents something crucial: proof that deep tech and biotech can thrive here, not as outposts of eastern seaboard companies, but as genuinely home-grown innovation. In a month dominated by global conflict and uncertainty, it's a reminder that some of the most meaningful progress happens in converted warehouses on quiet Subiaco streets.

This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.